PEA Technology: Quantification of protein biomarkers using minimal clinical sample volume

Advanced soluble biomarker quantification

CellCarta is the first global CRO to offer the Olink® Proximity Extension Assay (PEA) technology for clinical trials.

The unmatched high-multiplex technique allows for the quantification of protein biomarkers:

  • using minimal clinical sample volume (as low as 1 µL of blood),
  • with exceptional sensitivity and specificity,
  • while covering a broad dynamic range.

The integration of the Olink® Signature Q100 instruments with the Target 96 and Target 48 panels, Flex panels, and Focus assays into our laboratories will allow us to support biological mechanism studies driven by low abundant biomarkers such as immuno-oncology. 

Our team will address proteomic biomarkers needs for clinical trials, helping you investigate the mechanism of action of your new therapeutic or narrow down your list of potential clinical biomarkers.

About the PEA Technology

The Proximity Extension Assay (PEA)’s dual recognition approach is based on matched pairs of antibodies labeled with complementary DNA oligonucleotide tags. ​​​​

Once the target is bound, the oligonucleotides brought into proximity hybridize and are extended by standard PCR. This piece of DNA “barcode” created is unique for each antibody pair and is then amplified by quantitative PCR (qPCR).

PEA Technology: Available Panels and Assays

The Olink® Target 96 & Target 48 panels focus on specific disease areas or biological processes, and each enables the relative quantification of up to 92 carefully selected proteins across up to 88 samples simultaneously, using only 1µL of sample.

With Olink® Flex and Focus, panel customization is made easy.

Olink® Flex allows us to mix and match up to 21 proteins from a library of around 200 validated biomarkers into one panel with absolute quantification of up to 21 assays per panel and 40 samples per kit.

With Olink® Focus, we can deploy custom panels of up to 21 proteins developed by Olink.